Community pharmacies mood intervention study (CHEMIST)

Conditions

Depression Mental and Behavioural Disorders Mild depressive episode

Elizabeth Littlewood, Carolyn Chew‐Graham, Elizabeth Coleman, Samantha Gascoyne, Claire Sloan et al. (26 authors)

Public Health Research2022-03-016 citations

The feasibility and acceptability of a brief psychological intervention for adults with long-term health conditions and subthreshold depression delivered via community pharmacies: a mixed methods evaluation-the Community Pharmacies Mood Intervention Study (CHEMIST).

Chew-Graham CA, Kitchen CEW, Gascoyne S, Littlewood E, Coleman E, Bailey D, Crosland S, Pearson C, Ali S, Badenhorst J, Bambra C, Hewitt C, Jones C, Keding A, McMillan D, Sloan C, Todd A, Toner P, Whittlesea C, Watson M, Gilbody S, Ekers D.

2022-02-033 citations

10.1186/s40814-022-00992-7

Community Pharmacies Mood Intervention Study (CHEMIST): feasibility and external pilot randomised controlled trial protocol.

Littlewood E, Ali S, Badenhorst J, Bailey D, Bambra C, Chew-Graham C, Coleman E, Crosland S, Gascoyne S, Gilbody S, Hewitt C, Jones C, Keding A, Kitchen C, McMillan D, Pearson C, Rhodes S, Sloan C, Todd A, Watson M, Whittlesea C, Ekers D.

2019-05-293 citations

10.1186/s40814-019-0457-y

Interventions

Feasibility study: All participants receive the Enhanced Pharmacy Support Intervention (ESI). The ESI will be adapted for use with individuals with sub-threshold depression and long-term conditions, a

Proactive follow-up

Symptom monitoring

and Decision supported signposting. It will be delivered by suitably trained pharmacy support staff experienced in delivery of extended pharmacy roles (such as smoking cessation behavioural change app

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Adults (male or female, aged 18 years and over) 2. One or more long-term conditions (Arthritis, Cancer, Cardiovascular Conditions, Diabetes, Respiratory Conditions, Stroke). 3. Sub-threshold depression (screen positive with 2-4 symptoms confirmed by diagnostic assessment tool)

Exclusion criteria

Exclusion criteria: Current participant exclusion criteria as of 04/04/2019: 1. Alcohol or drug dependence 2. Cognitive impairment 3. Bipolar disorder or psychosis/psychotic symptoms 4. Actively suicidal (ascertained by eligibility screening interviews) 5. Currently in receipt of psychological therapy Previous participant exclusion criteria: 1. Alcohol or drug dependence 2. Cognitive impairment 3. Bipolar disorder or psychosis/psychotic symptoms 4. Acutely suicidal (ascertained by eligibility screening interviews) 5. Currently in receipt of psychological therapy

Design outcomes

Primary

Measure	Time frame
Feasibility Study: 1. Recruitment and attrition rates 2. Quality of data collection at baseline and 4 months 3. ESI adherence 4. Process evaluation is undertaken through qualitative interviews with participants, ESI facilitators and pharmacy staff Pilot RCT: Self-reported depression severity is measured by the Patient Health Questionnaire (PHQ9) at baseline and 4 months.	—

Secondary

Measure	Time frame
Pilot RCT: 1. Prevention of depression measured by binary depression scores on the PHQ9 at baseline and 4 months 2. Anxiety is measured using the GAD7 at baseline and 4 months 3. Health Related Quality of Life measured by the SF-12v2 at baseline and 4 months 4. Health State Utility measured by the EQ-5D at baseline and 4 months 5. Health Service Use, collected by a bespoke questionnaire (adapted AD-SUS) at baseline and 4 months 6. Participant’s use of Enhanced Support Intervention, collected from intervention facilitator records at 4 months 7. Process evaluation is undertaken using qualitative interviews with participants, pharmacy staff and GPs at 4 months	—

Measure

Time frame

Pilot RCT: 1. Prevention of depression measured by binary depression scores on the PHQ9 at baseline and 4 months 2. Anxiety is measured using the GAD7 at baseline and 4 months 3. Health Related Quality of Life measured by the SF-12v2 at baseline and 4 months 4. Health State Utility measured by the EQ-5D at baseline and 4 months 5. Health Service Use, collected by a bespoke questionnaire (adapted AD-SUS) at baseline and 4 months 6. Participant’s use of Enhanced Support Intervention, collected from intervention facilitator records at 4 months 7. Process evaluation is undertaken using qualitative interviews with participants, pharmacy staff and GPs at 4 months

—

Countries

England, United Kingdom

Contacts

Public ContactLiz Littlewood

liz.littlewood@york.ac.uk+44 1904 321828

Outcome results

None listed